<i>In vitro</i> efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian <i>Mycobacterium abscessus</i> isolates
Sulbactam/durlobactam significantly increased susceptibility to oral and intravenous β-lactam antibiotics in the form of cefuroxime, cefuroxime/amoxicillin and meropenem against clinical isolates of M. abscessus. This study also found significant differences in susceptibility to β-lactam antibiotics dependent on the culture media used, highlighting that the optimal culture methods for determining MIC in M. abscessus remains uncertain. Future in vivo studies are required to determine whether the in vitro efficacy of the β-lactam combinations studied could result in clinical efficacy for M. abscessus disease.
Authors
- Kirby Patterson-Fahy (ORCID: https://orcid.org/0009-0001-6937-7995)
- Rachel Mary Thomson (ORCID: https://orcid.org/0000-0003-0686-171X)
- Scott C. Bell (ORCID: https://orcid.org/0000-0001-8651-7139)
- Robyn Carter (ORCID: https://orcid.org/0000-0002-4524-6229)
- Andrew Burke (ORCID: https://orcid.org/0000-0002-2742-1556)
- Ieuan Evans (ORCID: https://orcid.org/0000-0002-9669-0805)
Institutions
- Griffith University (AU)
- The University of Queensland (AU)
- Gold Coast Hospital (AU)
- Princess Alexandra Hospital (AU)
- Gallipoli Medical Research Foundation (AU)
- Mayne Pharma (Australia) (AU)
- Prince Charles Hospital (AU)
- Princess Alexandra Hospital (GB)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1093/jac/dkaf441
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00